IRVINE, Calif.–(BUSINESS WIRE)—Masimo, uitvinder van metingen door beweging en pulsoxymetrie bij trage bloedsomloop, heeft vandaag zijn garantie van 1 miljoen dollar dat Masimo SET Pulse Oximetry alle pulsoxymeters van Nellcor (onderdeel van Covidien en thans Medtronic) overtreft. Indien aantoonbaar is vastgesteld dat Masimo SET niet beter is dan om het even welke pulsoxymeter van Nellcor, betaalt Masimo 1 miljoen dollar om een ziekenhuis te helpen bij het verkrijgen van die pulsoxymetrietechnologie.
“Als medisch-technologisch bedrijf geloven we dat het onze plicht is open en waarachtig te zijn in onze advertenties, want het gaat uiteindelijk om de zorg voor de patiënt. We staan nog altijd perplex van de misleidende marketingtactieken van onze concurrent”, verklaarde Joe Kiani, oprichter en ceo van Masimo. “Het baar ons zorgen dat klanten worden misleid en we hopen dat onze garantie hen ertoe aanzet vraagtekens te zetten bij dat wat ze horen en zelf de prestaties van de technologieën beoordelen.”
Masimo Renews its $1,000,000 Performance Guarantee that Masimo SET® Technology Will Outperform All Nellcor™ Pulse Oximeters
IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI), the inventor of measure-through motion and low perfusion pulse oximetry, today renewed its $1,000,000 (USD) performance guarantee that Masimo SET® Pulse Oximetry will outperform all Nellcor (part of Covidien and now Medtronic) pulse oximeters. Under the guarantee, if Masimo SET is proven not to be superior to all Nellcor pulse oximeters, including the three that Covidien announced have received FDA 510(k) clearance with motion claims, Masimo will pay up to $1,000,000 to help a hospital acquire that pulse oximetry.
Masimo makes four promises to every hospital that to date, Covidien has not been willing to make:
- We will demonstrate the superior pulse oximetry performance of Masimo SET® over Nellcor in a side-by-side comparison.
- We will provide independent and objective scientific evidence of Masimo SET® superiority over Nellcor, as well as the evidence demonstrating Masimo SET® helps clinicians improve clinical and financial outcomes.
- We strongly encourage scientific side-by-side evaluations of Masimo SET® and Nellcor pulse oximetry in challenging conditions with automated data collection.
- We are so confident that an objective comparison will reveal the clinical superiority of Masimo SET®, we continue to offer a $1,000,000 performance guarantee.
Please note: This offer is available only to hospitals whose goal is to upgrade their pulse oximetry hospital-wide to the new standard. Important details, conditions, and qualifications for the challenge are available at http://www.masimo.com/1millionrules.htm.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.@MasimoInnovates
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors related to MightySat, including our belief in the breakthrough ability of Masimo SET® pulse oximetry to measure-through motion and low perfusion; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation.
Irene Paigah, 858-859-7001
Check out our twitter: @NewsNovumpr